The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Discovery of a Novel cGAMP Competitive Ligand of the Inactive Form of STING
Open accessAbstract
Drugging large protein pockets is a challenge due to the need for higher molecular weight ligands, which generally possess undesirable physicochemical properties. In this communication, we highlight a strategy leveraging small molecule active site dimers to inhibit the large symmetric binding pocket in the STING protein. By taking advantage of the 2:1 binding stoichiometry, maximal buried interaction with STING protein can be achieved while maintaining the ligand physicochemical properties necessary for oral exposure. This mode of binding requires unique considerations for potency optimization including simultaneous optimization of protein–ligand as well as ligand–ligand interactions. Successful implementation of this strategy led to the identification of 18, which exhibits good oral exposure, slow binding kinetics, and functional inhibition of STING-mediated cytokine release.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Targeting STING with covalent small-molecule inhibitors
Haag, S. M., Gulen, M. F., Reymond, L., Gibelin, A., Abrami, L., Decout, A., Heymann, M., van der Goot, F. G., Turcatti, G., Behrendt, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0287-8 · Cited by 1,178
Cited by
The cGAS–STING pathway as a therapeutic target in inflammatory diseases
Decout, A., Katz, J. D., Venkatraman, S., & Ablasser, A. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00524-z · Cited by 2,309
An orally available non-nucleotide STING agonist with antitumor activity
Pan, B.-S., Perera, S. A., Piesvaux, J. A., Presland, J. P., Schroeder, G. K., Cumming, J. N., Trotter, B. W., Altman, M. D., Buevich, A. V., Cash, B., et al. (2020) · Science · doi:10.1126/science.aba6098 · Cited by 694
Self-citationOduro, P. K., Zheng, X., Wei, J., Yang, Y., Wang, Y., Zhang, H., Liu, E., Gao, X., Du, M., & Wang, Q. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.011 · Cited by 339
Signaling by cGAS–STING in Neurodegeneration, Neuroinflammation, and Aging
Paul, B. D., Snyder, S. H., & Bohr, V. A. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2020.10.008 · Cited by 314
Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway
Ding, C., Song, Z., Shen, A., Chen, T., & Zhang, A. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.03.001 · Cited by 306
Metadata
- Authors
- Siu, T., Altman, M. D., Baltus, G. A., Childers, M., Ellis, J. M., Gunaydin, H., Hatch, H., Ho, T., Jewell, J., Lacey, B. M., Lesburg, C. A., Pan, B.-S., Sauvagnat, B., Schroeder, G. K., & Xu, S.
- Venue
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-12-06
- Volume
- 10
- Issue
- 1
- Pages
- 92-97
- ISSN
- 1948-5875 (ISSN-L)
- OpenAlex
- W2904021876
- Cited by
- 179
- References
- 2
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery of a Novel cGAMP Competitive Ligand of the Inactive Form of STING. https://app.cochat.ai/papers/10.1021/acsmedchemlett.8b00466
- The paper
- Siu, T., Altman, M. D., Baltus, G. A., Childers, M., Ellis, J. M., Gunaydin, H., Hatch, H., Ho, T., Jewell, J., Lacey, B. M., Lesburg, C. A., Pan, B.-S., Sauvagnat, B., Schroeder, G. K., & Xu, S. (2019). Discovery of a Novel cGAMP Competitive Ligand of the Inactive Form of STING. ACS Medicinal Chemistry Letters. https://doi.org/10.1021/acsmedchemlett.8b00466
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.